睿昂基因(688217) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥48,273,660.16, representing a decrease of 25.47% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥2,331,194.58, a decline of 114.23% year-over-year[5] - Basic earnings per share were -¥0.04, reflecting a decrease of 113.79% year-over-year[5] - Total revenue for Q1 2022 was ¥48,273,660.16, a decrease of 25.5% compared to ¥64,770,985.83 in Q1 2021[22] - Net profit for Q1 2022 was a loss of ¥5,603,144.65, compared to a profit of ¥15,489,141.27 in Q1 2021[23] Research and Development - Research and development expenses totaled ¥19,953,750.23, accounting for 41.33% of operating revenue, an increase of 20.18 percentage points from the previous year[6] - The company continued to increase investment in digital PCR and second-generation sequencing research projects, leading to a significant rise in R&D expenses compared to the previous year[10] - Research and development expenses rose significantly to ¥19,953,750.23 in Q1 2022, up from ¥13,703,650.84 in Q1 2021, marking an increase of 45.5%[23] Cash Flow and Liquidity - The net cash flow from operating activities was ¥2,920,801.28, down 85.59% compared to the same period last year[5] - Cash received from sales and services was ¥49,583,348.96 in Q1 2022, down from ¥69,994,920.59 in Q1 2021, a decrease of 29.2%[26] - The net cash flow from operating activities for Q1 2022 was ¥2,920,801.28, a significant decrease of 85.6% compared to ¥20,263,907.68 in Q1 2021[27] - The net cash flow from investment activities for Q1 2022 was ¥6,035,453.83, a recovery from a negative cash flow of -¥45,691,974.45 in Q1 2021[28] - The ending balance of cash and cash equivalents as of Q1 2022 was ¥131,731,906.86, up from ¥108,313,342.24 in Q1 2021, reflecting an increase of 21.7%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥945,003,397.16, a slight decrease of 0.27% from the end of the previous year[6] - The total current assets decreased to RMB 525,948,300.42 from RMB 556,301,037.62, reflecting a decline of about 5.4%[18] - Total liabilities increased to ¥53,940,865.30 in Q1 2022 from ¥50,866,322.16 in Q4 2021[20] - The company's total equity decreased to ¥891,062,531.86 as of March 31, 2022, from ¥896,665,676.51 as of December 31, 2021[20] Market and Operational Impact - The decline in net profit was primarily attributed to the impact of the Spring Festival holiday and the COVID-19 pandemic in Shanghai, which affected sales revenue[9] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[15] - There are no significant mergers or acquisitions reported in the current quarter[15] Other Financial Metrics - The weighted average return on equity was -0.26%, a decrease of 2.76 percentage points compared to the previous year[6] - Total operating costs increased to ¥55,715,843.08 in Q1 2022 from ¥48,822,936.73 in Q1 2021, representing a rise of 14.5%[22] - Cash paid to employees in Q1 2022 was ¥21,258,779.11, an increase of 18.9% from ¥17,901,993.04 in Q1 2021[27] - The cash flow from financing activities was not detailed in the report, indicating potential areas for future disclosure[28]